FDA Grants Breakthrough Status to Freesolve Scaffold
The resorbable device aims to offer U.S. heart patients an alternative to permanent implants.
Updated on Oct. 22, 2026 in Heart Disease
Live Poll
Do you trust that new medical device innovations generally lead to better long-term patient health outcomes?
The FDA has granted Breakthrough Device designation to the Freesolve resorbable scaffold. This technology, acquired by Teleflex in 2025, is designed to support vessels before being absorbed by the body.
Why it matters
The Breakthrough Device program aims to expedite the review of products that could offer more effective treatment options than existing standards. This designation could accelerate the availability of the device for patients in the United States who need vessel support without the long-term presence of a permanent implant.
The device demonstrated a 3.5% target lesion failure rate at four years of observation. Additionally, 99% of the BIOmag magnesium alloy used in the scaffold is absorbed into the human body after one year.
The players
Teleflex
Teleflex is a global provider of medical technology products for critical care and surgery.
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by regulating medical devices.
Biotronik
Biotronik is a medical technology company that develops cardiovascular and endovascular solutions.
The details
The catheter-delivered system utilizes a bioabsorbable coating technology to maintain vessel integrity during the healing process. Teleflex intends to bring this product, currently available in select Asian-Pacific, South American, and Middle Eastern markets, to the U.S. healthcare system.
Timeline
Teleflex acquired the device from Biotronik in 2025.
Teleflex was ranked the 55th largest medical device company by revenue in 2026.
The FDA announced the designation on October 22, 2026.
Health Landscape
The FDA Breakthrough Device program facilitates the development of medical technologies that address unmet needs for life-threatening or irreversibly debilitating conditions. This move marks the latest expansion of resorbable scaffold technology into the U.S. market, building on established use in other international regions.
If approved for use, this device could offer patients an alternative to traditional permanent implants that remain in the body indefinitely. The resorbable nature of the scaffold aims to reduce potential long-term complications associated with metal implants in the heart.
The takeaway
The transition from permanent implants to resorbable scaffolds represents a significant shift in cardiovascular intervention technology. Patients and healthcare providers should monitor future clinical trial results to understand how these devices perform compared to traditional metal stents.
Further reading
Learn more about the latest innovations in cardiac care by visiting our Heart Disease section.
Live Poll
Do you trust that new medical device innovations generally lead to better long-term patient health outcomes?
